Detail akcie Sorrento Thera online

Business Summary: Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. It is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.
Financial Summary: BRIEF: For the six months ended 30 June 2023, Sorrento Therapeutics Inc revenues increased 5% to $31.3M. Net loss decreased 10% to $234.7M. Revenues reflect Scilex segment increase of 57% to $23.2M. Lower net loss reflects Sorrento Therapeutics segment loss decrease of 33% to $136.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.66 to -$0.43.